From a therapeutic perspective, ferroptosis can be suppressed by radical-trapping antioxidants (ferrostatin-1, liproxstatin-1 and derivatives) or, conversely, induced by PUFA supplementation, GPX4/FSP1 inhibition, or SCD blockade, highlighting clinical opportunities to either mitigate oxidative liver injury or trigger ferroptotic death in hepatocellular carcinoma (Fig. 1B). This evidence concerns the gene GPX4 and hepatocellular carcinoma.